365 related articles for article (PubMed ID: 11889373)
1. Risk factors and demographics in patients with spasmodic dysphonia.
Schweinfurth JM; Billante M; Courey MS
Laryngoscope; 2002 Feb; 112(2):220-3. PubMed ID: 11889373
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of essential voice tremor: a study of 34 cases.
Sulica L; Louis ED
Laryngoscope; 2010 Mar; 120(3):516-28. PubMed ID: 20066728
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
Hogikyan ND; Wodchis WP; Spak C; Kileny PR
J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
[TBL] [Abstract][Full Text] [Related]
4. Case-control study of risk factors for spasmodic dysphonia: A comparison with other voice disorders.
Tanner K; Roy N; Merrill RM; Sauder C; Houtz DR; Smith ME
Laryngoscope; 2012 May; 122(5):1082-92. PubMed ID: 22253036
[TBL] [Abstract][Full Text] [Related]
5. Patient perceptions of factors leading to spasmodic dysphonia: a combined clinical experience of 350 patients.
Childs L; Rickert S; Murry T; Blitzer A; Sulica L
Laryngoscope; 2011 Oct; 121(10):2195-8. PubMed ID: 21898448
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results.
Paniello RC; Barlow J; Serna JS
Laryngoscope; 2008 Mar; 118(3):564-8. PubMed ID: 18216744
[TBL] [Abstract][Full Text] [Related]
7. [Psychological factors in spasmodic dysphonia].
Kiese-Himmel C; Zwirner P
Laryngorhinootologie; 1996 Jul; 75(7):397-402. PubMed ID: 8924167
[TBL] [Abstract][Full Text] [Related]
8. Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia.
Anari S; Carding PN; Hawthorne MR; Deakin J; Drinnan MJ
Laryngoscope; 2007 Oct; 117(10):1888-92. PubMed ID: 17690610
[TBL] [Abstract][Full Text] [Related]
9. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia.
Stong BC; DelGaudio JM; Hapner ER; Johns MM
Arch Otolaryngol Head Neck Surg; 2005 Sep; 131(9):793-5. PubMed ID: 16172357
[TBL] [Abstract][Full Text] [Related]
10. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia.
Adams SG; Hunt EJ; Irish JC; Charles DA; Lang AE; Durkin LC; Wong DL
J Otolaryngol; 1995 Dec; 24(6):345-51. PubMed ID: 8699600
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.
Rubin AD; Wodchis WP; Spak C; Kileny PR; Hogikyan ND
Arch Otolaryngol Head Neck Surg; 2004 Apr; 130(4):415-20. PubMed ID: 15096423
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital.
Srirompotong S; Saeseow P; Taweesaengsuksakul R; Kharmwan S; Srirompotong S
J Med Assoc Thai; 2006 Dec; 89(12):2077-80. PubMed ID: 17214059
[TBL] [Abstract][Full Text] [Related]
13. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients.
Walling HW
J Am Acad Dermatol; 2009 Aug; 61(2):242-6. PubMed ID: 19395123
[TBL] [Abstract][Full Text] [Related]
14. Self-reported impact of dysphonia in a primary care population: an epidemiological study.
Cohen SM
Laryngoscope; 2010 Oct; 120(10):2022-32. PubMed ID: 20830762
[TBL] [Abstract][Full Text] [Related]
15. Psychological aspects of adductor spasmodic dysphonia: a prospective population controlled questionnaire study.
Kaptein AA; Hughes BM; Scharloo M; Hondebrink N; Langeveld TP
Clin Otolaryngol; 2010 Feb; 35(1):31-8. PubMed ID: 20447160
[TBL] [Abstract][Full Text] [Related]
16. Toward improved differential diagnosis of adductor spasmodic dysphonia and muscle tension dysphonia.
Roy N; Mauszycki SC; Merrill RM; Gouse M; Smith ME
Folia Phoniatr Logop; 2007; 59(2):83-90. PubMed ID: 17337898
[TBL] [Abstract][Full Text] [Related]
17. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
Meyer TK; Hu A; Hillel AD
Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.
Casserly P; Timon C
J Laryngol Otol; 2008 Jan; 122(1):52-6. PubMed ID: 17470307
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic difficulties in spasmodic dysphonia--case report].
Szkiełkowska A; Miaśkiewicz B; Baczyńska-Swierczyńska S; Szymańska E
Pol Merkur Lekarski; 2006 May; 20(119):557-9. PubMed ID: 16875162
[TBL] [Abstract][Full Text] [Related]
20. Central auditory evaluation of patients with spasmodic dysphonia.
Middleton ML; Wilson KM; Keith RW
Ear Nose Throat J; 1997 Oct; 76(10):710-5. PubMed ID: 9345814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
